# Eric Green

> Eric Green is the Founder and CEO of Trace Neuroscience, a South San Francisco biotech company racing to develop the first effective ASO therapy for ALS. A Harvard-and-Stanford-trained physician-scientist with a background in cardiology, Green co-founded iLab Solutions (acquired by Agilent), Respira Design (Stanford $50K Challenge winner), and Maze Therapeutics before launching Trace with a $101 million Series A in November 2024. Trace's lead program targets UNC13A - a protein lost in ALS patients - using an antisense oligonucleotide designed to restore healthy nerve-muscle communication. With clinical trials targeting early 2026, Green is betting human genetics can do for ALS what it did for heart failure.

- **Role:** Founder and CEO at Trace Neuroscience
- **Organizations:** Trace Neuroscience, Maze Therapeutics, MyoKardia, Third Rock Ventures, iLab Solutions, Respira Design, Brigham and Women's Hospital, Harvard Medical School
- **Nationality:** American
- **Education:** A.B. in History and Science, Harvard College, M.D. and Ph.D. in Chemical and Systems Biology, Stanford University, Residency and Fellowship, Internal Medicine and Cardiovascular Medicine, Brigham and Women's Hospital
- **Known for:** Raised $101 million Series A for Trace Neuroscience at launch in November 2024, Co-founded and led translational science at MyoKardia, contributing to mavacamten's FDA approval and the company's $13 billion acquisition by Bristol Myers Squibb, Co-founded Maze Therapeutics, pioneering a human-genetics-first platform for precision medicine across rare diseases

## Career timeline

- **~1994-1998** — Undergraduate at Harvard College; worked in Greg Verdine's chemistry lab developing early scientific curiosity
- **~1998-2008** — MD-PhD at Stanford University in Chemical and Systems Biology; co-founded iLab Solutions (scheduling software for research core facilities) with college roommate - later acquired by Agilent
- **~2003** — Co-founded Respira Design, a medical device company targeting asthma in developing nations; won the Stanford $50K Entrepreneurship Challenge
- **~2008-2013** — Cardiology fellowship at Brigham and Women's Hospital; Instructor in Medicine at Harvard Medical School
- **2013** — Joined Third Rock Ventures as associate; involved in launching Element Science, MyoKardia, Goldfinch Bio, Cibiem
- **2013-2017** — Led translational research group at MyoKardia, working on mavacamten for hypertrophic cardiomyopathy
- **2017** — Returned to Third Rock Ventures as Entrepreneur-in-Residence; co-founded Maze Therapeutics
- **2017-2023** — Chief Scientific Officer (and SVP Research & Translational Sciences) at Maze Therapeutics, building a human genetics-driven precision medicine platform; collaborated with Aaron Gitler (Stanford) on ALS research
- **2021** — MyoKardia acquired by Bristol Myers Squibb for $13 billion; mavacamten later received FDA approval
- **2023** — Co-founded Trace Neuroscience with Aaron Gitler (Stanford), Pietro Fratta (UCL/Francis Crick Institute), and Michael Ward (NIH)
- **2024-11** — Trace Neuroscience launches publicly with $101 million Series A led by Third Rock Ventures, Atlas Venture, GV, and RA Capital Management
- **2025** — Trace Neuroscience named a Fierce 15 Biotech Company of 2025; planning IND filing and clinical trial initiation

## Achievements

- Raised $101 million Series A for Trace Neuroscience at launch in November 2024
- Co-founded and led translational science at MyoKardia, contributing to mavacamten's FDA approval and the company's $13 billion acquisition by Bristol Myers Squibb
- Co-founded Maze Therapeutics, pioneering a human-genetics-first platform for precision medicine across rare diseases
- Co-founded iLab Solutions (scheduling software for research core facilities), later acquired by Agilent
- Co-founded Respira Design, winner of Stanford $50K Entrepreneurship Challenge
- Named Fierce 15 Biotech Company of 2025 (Trace Neuroscience)
- Assembled four co-founders who independently made convergent discoveries about UNC13A and TDP-43 in ALS
- Board-certified physician in Internal Medicine and Cardiovascular Medicine

## Latest updates

- **2025-05** — Trace Neuroscience featured in Fierce 15 Biotech Companies of 2025; advancing lead ASO program toward IND and clinical trial initiation
- **2024-12** — Eric Green appeared on The Genetics Podcast discussing Trace Neuroscience's science and his journey from cardiology to ALS drug development
- **2024-11** — Trace Neuroscience launched publicly with $101M Series A led by Third Rock Ventures, Atlas Venture, GV, and RA Capital Management

## Links

- Website: https://traceneuro.com
- LinkedIn: http://www.linkedin.com/in/eric-green-21058b4

---

Profile page: https://yespress.io/eric-green
Published by YesPress — https://yespress.io
Last updated: 2026-05-14